Dai Wei, Dong Jifu, Zhang Hongwei, Yang Xiaojun, Li Qiang
Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
Department of Anesthesiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
J Thorac Dis. 2018 Jan;10(1):363-370. doi: 10.21037/jtd.2017.12.130.
Superior vena cava (SVC) replacement is infrequently performed and technically challenging in low-volume centers. Venovenous shunt (VVS) technique is used to reduce SVC pressure during SVC replacement and has not been well reported. This study aimed to add information on this subject and evaluate the surgical outcomes of patients who underwent SVC replacement combined with VVS in our center.
A retrospective analysis of six patients who underwent SVC replacement combined with VVS from September 2011 to February 2017 was performed. Clinical characteristics, pathological features, operative characteristics, postoperative outcomes, and the survival of the six patients were reviewed.
There were four males and two females with a median age of 44 years (range, 35-69 years). There were three lung cancer patients and three thymoma patients at a stage from IIIA to IVA. Five patients underwent induction therapy. Complete resection was performed on five patients. One patient underwent internal VVS, and the other five patients underwent external VVS. Prosthesis grafts were employed in five cases and autologous pericardium in one case. Three patients underwent single-vein reconstruction, and the other three patients underwent double-vein reconstruction. The median SVC clamping time was 75 minutes. There were no postoperative deaths or major complications. All patients were alive at follow-up, and no thrombosis was found in any of the grafts.
SVC replacement combined with VVS is technically feasible and safe. Although VVS technique is not a must, it may make SVC replacement safer in inexperienced centers. Surgery-based multidisciplinary treatment for selected patients with type T4 lung cancer and SVC involvement or thymoma and SVC involvement may achieve a favorable long-term outcome.
上腔静脉(SVC)置换术在低容量中心较少进行,且技术上具有挑战性。静脉-静脉分流(VVS)技术用于在SVC置换期间降低SVC压力,但相关报道较少。本研究旨在补充这方面的信息,并评估在我们中心接受SVC置换联合VVS的患者的手术结果。
对2011年9月至2017年2月期间接受SVC置换联合VVS的6例患者进行回顾性分析。回顾了这6例患者的临床特征、病理特征、手术特征、术后结果和生存情况。
男性4例,女性2例,中位年龄44岁(范围35 - 69岁)。有3例肺癌患者和3例胸腺瘤患者,分期为IIIA至IVA期。5例患者接受了诱导治疗。5例患者进行了完整切除。1例患者接受了内部VVS,其他5例患者接受了外部VVS。5例使用了人工血管移植物,1例使用了自体心包。3例患者进行了单静脉重建,其他3例患者进行了双静脉重建。SVC阻断时间的中位数为75分钟。术后无死亡或重大并发症。所有患者在随访时均存活,且任何移植物均未发现血栓形成。
SVC置换联合VVS在技术上是可行且安全的。虽然VVS技术并非必需,但它可能使经验不足的中心进行SVC置换更安全。对于选定的T4型肺癌合并SVC受累或胸腺瘤合并SVC受累的患者,基于手术的多学科治疗可能取得良好的长期效果。